Hence, our data indicate that downregulation of Atg7 sensitizes CRC cells towards Irinotecan and 5-FU treatment, additionally emphasizing the therapeutic potential of targeting Atg7 alone or as a combinatorial approach in CRC. The gene discussed is ATG7; the disease is colorectal carcinoma.